Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy - PubMed
5 hours ago
- #CAR T-cell therapy
- #Large B-cell lymphoma
- #Metabolic tumor volume
- CAR T-cell therapy is effective for relapsed/refractory large B-cell lymphoma (LBCL), but identifying nonresponders beforehand remains unclear.
- Metabolic tumor volume (MTV) from PET imaging is a promising biomarker for predicting outcomes in LBCL patients undergoing CAR T-cell therapy.
- The study compared MTV with the International Prognostic Index (IPI) in predicting progression-free survival (PFS) in 111 LBCL patients from multiple centers.
- MTV showed better predictive accuracy for PFS than IPI, with an area under the curve of 0.68 and Harrell C-index of 0.59.
- A combined risk model of MTV and extranodal involvement performed well but was not superior to MTV alone.
- MTV alone outperformed IPI in predicting PFS, suggesting its potential role in individualized bridging strategies for LBCL patients.